{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:22:26Z","timestamp":1762608146779,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005278","name":"University of Antioquia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaip.2025.03.035","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:16:44Z","timestamp":1743639404000},"page":"1776-1785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Head-to-Head Effectiveness Comparison of Biological Therapies in Patients With Mixed Eosinophilic and Allergic Severe Asthma"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6341-783X","authenticated-orcid":false,"given":"Jorge","family":"S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leidy","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana-Lorena","family":"Caraballo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis-Carlos","family":"Santamaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana-Milena","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Calle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Olivares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.03.035_bib1","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.jaip.2020.11.053","article-title":"Potential severe asthma hidden in UK primary care","volume":"9","author":"Ryan","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.03.035_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12931-018-0719-x","article-title":"Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR)","volume":"19","author":"Larsson","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2025.03.035_bib3","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jaip.2024.02.029","article-title":"Comparative impact of asthma biologics: a nationwide US claim-based analysis","volume":"12","author":"Al-Shaikhly","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.03.035_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107528","article-title":"Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy","volume":"222","author":"Breslavsky","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.03.035_bib5","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1164\/rccm.200902-0166OC","article-title":"The prevalence of nonadherence in difficult asthma","volume":"180","author":"Gamble","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.03.035_bib6","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2147\/JAA.S327659","article-title":"Severe asthma in a general population study: prevalence and clinical characteristics","volume":"14","author":"R\u00f6nnebjerg","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.03.035_bib7","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s00405-024-08461-y","article-title":"Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP","volume":"281","author":"Rosso","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jaip.2025.03.035_bib8","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jaip.2024.03.049","article-title":"Long-term effectiveness of anti-IL4R therapy following suboptimal response to anti-IL5\/5R therapy in severe eosinophilic asthma","volume":"12","author":"Gates","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.03.035_bib9","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.jaip.2024.03.037","article-title":"Asthma loss of control after switch from anti-IL5\/5R drugs to dupilumab in severe eosinophilic asthma: a case series","volume":"12","author":"Poisson","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.03.035_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MCP.0000000000001067","article-title":"Long-term safety, durability of response, cessation and switching of biologics","volume":"30","author":"Mohan","year":"2024","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jaip.2025.03.035_bib11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jaip.2024.01.023","article-title":"Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics","volume":"12","author":"Bourdin","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.03.035_bib12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/ijms25010182","article-title":"Personalized medicine in severe asthma: from biomarkers to biologics","volume":"25","author":"Chen","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2025.03.035_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100520","article-title":"IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma","volume":"14","author":"S\u00e1nchez","year":"2021","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2025.03.035_bib14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/02770903.2023.2263072","article-title":"Tropical high altitude and severe asthma in adults: house dust mite sensitization and phenotypic distribution","volume":"61","author":"Torres-Duque","year":"2024","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2025.03.035_bib15","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaci.2022.11.021","article-title":"Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"151","author":"Nopsopon","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.03.035_bib16","article-title":"Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma","volume":"191","author":"Bateman","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.03.035_bib17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/13696998.2022.2074195","article-title":"Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison","volume":"25","author":"Menzies-Gow","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.jaip.2025.03.035_bib18","doi-asserted-by":"crossref","first-page":"00306","DOI":"10.1183\/23120541.00306-2021","article-title":"Indirect comparison of efficacy of dupilumab","volume":"7","author":"Pr\u00e6torius","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2025.03.035_bib20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.25100\/cm.v49i2.3015","article-title":"Clinical differences between children with asthma and rhinitis in rural and urban areas","volume":"49","author":"Sanchez","year":"2018","journal-title":"Colomb Med (Cali)"},{"key":"10.1016\/j.jaip.2025.03.035_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0137-2019","article-title":"Minimal clinically important difference for asthma endpoints: an expert consensus report","volume":"29","author":"Bonini","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2025.03.035_bib22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.03.035_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100760","article-title":"The use of systemic corticosteroids in asthma management in Latin American countries","volume":"16","author":"Maspero","year":"2023","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2025.03.035_bib24","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2147\/JAA.S365009","article-title":"A cross-sectional study on prescription patterns of short-acting \u03b2","volume":"15","author":"Pedrozo-Pupo","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.03.035_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00598-2019","article-title":"The Global Initiative for Asthma (GINA): 25 years later","volume":"54","author":"Boulet","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.03.035_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3949\/ccjm.87a.19136","article-title":"Managing adult asthma: the 2019 GINA guidelines","volume":"87","author":"Mauer","year":"2020","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jaip.2025.03.035_bib28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","article-title":"Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"150","author":"Akenroye","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.03.035_bib29","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/0897190019840597","article-title":"Comparison of monoclonal antibodies for treatment of uncontrolled eosinophilic asthma","volume":"33","author":"Koski","year":"2020","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.jaip.2025.03.035_bib30","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/all.16091","article-title":"Meta-analysis in allergy-statistical recommendations","volume":"79","author":"Ordak","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.03.035_bib31","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2023.01.020","article-title":"Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a target trial emulation","volume":"151","author":"Akenroye","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.03.035_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12890-024-02964-4","article-title":"Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy","volume":"24","author":"Kayser","year":"2024","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2025.03.035_bib33","first-page":"37","article-title":"Improvement in olfaction in patients with CRSwNP and severe asthma taking anti-IgE and anti-IL-5 biologics: a real-life study","volume":"33","author":"Barroso","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2025.03.035_bib34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000519228","article-title":"Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis","volume":"183","author":"Wu","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.03.035_bib35","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.jaip.2023.04.033","article-title":"Nonsteroidal anti-inflammatory drug (NSAID) tolerance after biological therapy in patients with NSAID-exacerbated respiratory disease: a randomized comparative trial","volume":"11","author":"S\u00e1nchez","year":"2023","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825002983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825002983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:17:37Z","timestamp":1762607857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825002983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2213219825002983"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.03.035","relation":{},"ISSN":["2213-2198"],"issn-type":[{"type":"print","value":"2213-2198"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Head-to-Head Effectiveness Comparison of Biological Therapies in Patients With Mixed Eosinophilic and Allergic Severe Asthma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.03.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}